Methotrexate therapy for squamous cell carcinomas of the head and neck. Intermittent intravenous dose program.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004428:Ear Neoplasms / Q000188:drug therapy; D004825:Epiglottis; D005153:Facial Neoplasms / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy*; D010157:Palatal Neoplasms / Q000188:drug therapy; D010610:Pharyngeal Neoplasms / Q000188:drug therapy; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D008727:Methotrexate